Synonym
Reltecimod sodium; AB103 sodium; AB 103 sodium; AB-103 sodium
IUPAC/Chemical Name
sodium (S)-3-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-1-(D-alanyl-L-seryl)pyrrolidine-2-carboxamido)-4-(methylthio)butanamido)-4-methylpentanamido)-3-methylbutanamido)propanamido)-3-(4-hydroxyphenyl)propanamido)-4-(((R)-1-carboxyethyl)amino)-4-oxobutanoate
InChi Key
GQYCKGDMCOZFKT-CHDMJDELSA-M
InChi Code
InChI=1S/C46H72N10O15S.Na/c1-22(2)18-30(52-39(63)29(15-17-72-8)50-43(67)34-10-9-16-56(34)45(69)33(21-57)54-37(61)24(5)47)42(66)55-36(23(3)4)44(68)48-25(6)38(62)51-31(19-27-11-13-28(58)14-12-27)41(65)53-32(20-35(59)60)40(64)49-26(7)46(70)71;/h11-14,22-26,29-34,36,57-58H,9-10,15-21,47H2,1-8H3,(H,48,68)(H,49,64)(H,50,67)(H,51,62)(H,52,63)(H,53,65)(H,54,61)(H,55,66)(H,59,60)(H,70,71);/q;+1/p-1/t24-,25+,26-,29+,30+,31+,32+,33+,34+,36+;/m1./s1
SMILES Code
CSCC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(O)=O)C)=O)CC([O-])=O)=O)CC1=CC=C(O)C=C1)=O)C)=O)C(C)C)=O)CC(C)C)=O)NC([C@@H]2CCCN2C([C@@H](NC([C@H](N)C)=O)CO)=O)=O.[Na+]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
1,059.18
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY Sr, Kim HY, Ryu EK, Murugan RN, Kim NH, Bang JK. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. J Med Chem. 2015 Jan 8;58(1):294-304. doi: 10.1021/jm501147g. Epub 2014 Nov 5. PubMed PMID: 25347203.
2: LIDDLE HV, THOMAS JM. AB-103 (NSC-37096) IN THE TREATMENT OF BRONCHOGENIC CARCINOMA. Cancer Chemother Rep. 1964 Jul;39:61-5. PubMed PMID: 14201277.
3: MECHL Z, KOLAR V, KONECNY M. THE USE OF THE DRUGS AB 103 AND AB 132 IN THE COMBINED TREATMENT OF TUMOURS OF THE CERVICAL AND PULMONARY REGIONS. Neoplasma. 1964;11:491-8. PubMed PMID: 14220338.
4: NEVINNY-STICKEL HB, DEDERICK MM, HAINES CR, HALL TC. A STUDY OF BENZCARBIMINE (AB-103; NSC-37096) IN PATIENTS WITH VARIOUS MALIGNANCIES. Cancer Chemother Rep. 1963 Dec;33:15-20. PubMed PMID: 14102077.
5: MOERTEL CG, REITEMEIER RJ, HAHN RG. AN EVALUATION OF AB-103 (NSC-37096) IN THE PALLIATIVE MANAGEMENT OF ADVANCED GASTROINTESTINAL CARCINOMA. Cancer Chemother Rep. 1963 Oct;32:97-8. PubMed PMID: 14088841.
6: COPPOLA ED, DEJODE LR, HOWARD JM. Studies of homotransplantation of the kidney in dogs treated with an experimental cancer chemotherapeutic agent (AB-103). Surg Gynecol Obstet. 1962 Jul;115:80-8. PubMed PMID: 13881232.
7: RAZIS DV, AMBRUS JL, ROSS CA, STUTZMAN L, SOKAL JE, REJALI AM, BARDOS TJ. Use of AB-103 (a "dual antagonist") in the treatment of bronchogenic carcinoma. Cancer. 1961 Jul-Aug;14:853-61. PubMed PMID: 13740023.
8: RAZIS DV, AMBRUS JL, ROSS CA, STUTZMAN L, SOKAL JE, REJALI AB. AB-103, a new chemotherapeutic agent in the treatment of bronchogenic carcinoma-a preliminary report. Cancer Chemother Rep. 1960 Nov;9:37-8. PubMed PMID: 13740022.
